Table 1.

Relative abundance of modified peptides identified by mass spectrometry

Relative abundance
Residue Cortactin peptide sequence (mouse) (+) Inhibitors (-) Inhibitors
S11   ASAGHAVSITQDDG   IMAC   -  
S11   KASAGHAVSITQDDGGADDW   ++   -  
S11   KASAGHAVSITQDDGGADDWETDPDFVNDVSEKEQRW   ++++   -  
S11   ASAGHAVSITQDDGGADDWETDPDFVNDVSEK   ++++   -  
[S11-T13]   KASAGHAV[SIT]QDDGGADDWETDPDFVNDVSEKEQRW   +++   -  
T13   ASAGHAVSITQDDG   IMAC   -  
T13   ASAGHAVSITQDDGGADDWETDPDFVNDVSEK   ++++   -  
T13   ASAGHAVSITQDDGGADDWETDPDFVNDVSEKEQRWGAK   ++++   -  
T24   ASAGHAVSITQDDGGADDWETDPDFVNDVSEK   IMAC   -  
S135   GVQMDRVDQSAVGF   IMAC   -  
S150   EYQGKTEKHASQKDY   IMAC   -  
S172   GVQADRVDKSAVGF   ++   IMAC  
T182   DYQGKTEKHESQKDY   IMAC   -  
S209   GIDKDKVDKSAVGF   IMAC   IMAC  
S282   GVQSERQDSSAVGF   IMAC   -  
S283   GVQSERQDSSAVGF   IMAC   ++++  
S283   FGVQSERQDSSAVGF   IMAC   -  
S322   GVQKDRMDKNASTFEEVVQVPSAY   ++++   -  
[S322-T323]   NA[ST]FEEVVQVPSAYQK   +   -  
S345   QKTVPIEAVTSKTSNIRANF   IMAC   -  
S348   QKTVPIEAVTSKTSNIRANF   IMAC   IMAC  
S407/[S417-Y421]   KQTPPASPSPQPIEDRPP[SSPIY]EDAAPF   ++   -  
[S417-S418]   RPP[SS]PIYEDAAPF   IMAC   -  
[S417-S418]   DRPP[SS]PIYEDAAPF   IMAC   -  
S454   KAEPSYRGSEPEPEYSIEAAGIPEAGSQQGLTY   ++   -  
T468   ETTEAPGHYQAEDDTY   IMAC   -  
Y475   ETTEAPGHYQAEDDTY   IMAC   -  
Relative abundance
Residue Cortactin peptide sequence (mouse) (+) Inhibitors (-) Inhibitors
S11   ASAGHAVSITQDDG   IMAC   -  
S11   KASAGHAVSITQDDGGADDW   ++   -  
S11   KASAGHAVSITQDDGGADDWETDPDFVNDVSEKEQRW   ++++   -  
S11   ASAGHAVSITQDDGGADDWETDPDFVNDVSEK   ++++   -  
[S11-T13]   KASAGHAV[SIT]QDDGGADDWETDPDFVNDVSEKEQRW   +++   -  
T13   ASAGHAVSITQDDG   IMAC   -  
T13   ASAGHAVSITQDDGGADDWETDPDFVNDVSEK   ++++   -  
T13   ASAGHAVSITQDDGGADDWETDPDFVNDVSEKEQRWGAK   ++++   -  
T24   ASAGHAVSITQDDGGADDWETDPDFVNDVSEK   IMAC   -  
S135   GVQMDRVDQSAVGF   IMAC   -  
S150   EYQGKTEKHASQKDY   IMAC   -  
S172   GVQADRVDKSAVGF   ++   IMAC  
T182   DYQGKTEKHESQKDY   IMAC   -  
S209   GIDKDKVDKSAVGF   IMAC   IMAC  
S282   GVQSERQDSSAVGF   IMAC   -  
S283   GVQSERQDSSAVGF   IMAC   ++++  
S283   FGVQSERQDSSAVGF   IMAC   -  
S322   GVQKDRMDKNASTFEEVVQVPSAY   ++++   -  
[S322-T323]   NA[ST]FEEVVQVPSAYQK   +   -  
S345   QKTVPIEAVTSKTSNIRANF   IMAC   -  
S348   QKTVPIEAVTSKTSNIRANF   IMAC   IMAC  
S407/[S417-Y421]   KQTPPASPSPQPIEDRPP[SSPIY]EDAAPF   ++   -  
[S417-S418]   RPP[SS]PIYEDAAPF   IMAC   -  
[S417-S418]   DRPP[SS]PIYEDAAPF   IMAC   -  
S454   KAEPSYRGSEPEPEYSIEAAGIPEAGSQQGLTY   ++   -  
T468   ETTEAPGHYQAEDDTY   IMAC   -  
Y475   ETTEAPGHYQAEDDTY   IMAC   -  

Each of the modified peptides identified from cortactin is listed, with the phosphorylated residue(s) shown in red. Phosphorylation sites in brackets could not be specified unambiguously. In most experiments, the cells were treated with phosphatase inhibitors before lysis. Relative peptide abundance is expressed in terms of peak areas observed for all charge states of particular peptides. Peak areas for the most abundant phosphopeptides are displayed as ++++; those with areas that are decreased by a factor of 10, 100 and 1000 are shown as +++, ++ and +, respectively. Phosphopeptides that were not identified without inhibitor treatment are indicated as -. Peptides labeled `IMAC' were only observed after enrichment of the sample by immobilized metal-affinity chromatography.

Close Modal

or Create an Account

Close Modal
Close Modal